Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
Mercedes-Benz to Release Luxury Electric Van in China 
Whirlpool’s Stale Demand Led to 1,000 Job Cuts in the US 
Why is the London Stock Exchange losing out to the US 
Family farms are fast disappearing: our research shows how young generations can take them up successfully 
Ferrari F1 Announces Multi-Year Partnership with HP as Title Sponsor 
LATAM Airlines Abandons Plans to Acquire Boeing B737 Planes Amid Gol Bankruptcy 
SK Networks Sets Up AI Research Lab in Silicon Valley 
Tesla Model 3 Performance Eligible for $7,500 Tax Credit, Launches at $53K 
Hybe Accuses ADOR Subsidiary’s CEO of Breach of Trust 
Hermes Surpasses Expectations with a 17% Surge in First-Quarter Sales 
GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
TikTok Vows to Fight US Ban After Biden Signed Bill 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production 
IBM Acquires HashiCorp, Giving Its Hybrid-Cloud Business a Boost 
AUSTIN, Texas, Dec. 07, 2016 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer, today announced that it will participate on a panel and provide a corporate update at the upcoming BMO Capital Markets Prescription for Success Healthcare Conference on Wednesday, December 14, 2016 in New York.
David G. Lowe, Ph.D., president and chief executive officer of Aeglea, will participate on a panel entitled, “The New Generation of Orphan Companies,” which will take place at 9:40 a.m. ET in the Empire Ballroom at the InterContinental Barclay Hotel. The corporate update will follow at 11:00 a.m. ET in the Empire Ballroom I.
The corporate update presentation will be webcast live and available on the company website at aegleabio.com/investors. The webcast and presentation will be archived for viewing for 90 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing engineered human enzymes for the treatment of genetic rare diseases and cancer associated with abnormal amino acid metabolism. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in genetic rare diseases or to deprive tumors dependent on amino acids by reducing levels below the normal range. Aeglea’s clinical program for its lead product candidate, AEB1102, includes three Phase 1 clinical trials, studying AEB1102 for the treatment of patients with Arginase I deficiency, advanced solid tumors and hematological malignancies. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocysteine, a target for a genetic rare disease, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine. For more information, visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D. BrewLife 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
